• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Stevanato Group S.p.A.

    2/12/24 4:26:16 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care
    Get the next $STVN alert in real time by email
    SC 13G 1 formsc13g-02122024_090212.htm FORM schedule-13g


     
     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934


     
    Stevanato Group S.p.A.
    (Name of Issuer)
    Common
    (Title of Class of Securities)
    T9224W109
    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ x ] Rule 13d-1(b)

    [   ] Rule 13d-1(c)

    [   ] Rule 13d-1(d)



    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.


    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     


     
    CUSIP No. T9224W109
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Group LLC

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)   Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        0

       (6)   

    Shared Voting Power

     

        3,346,671

       (7)   

    Sole Dispositive Power

     

        0

       (8)   

    Shared Dispositive Power

     

        3,385,317

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        3,385,317

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        9.93%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        HC


    CUSIP No. T9224W109
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Investment Advisers LLC

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)   Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        0

       (6)   

    Shared Voting Power

     

        3,346,671

       (7)   

    Sole Dispositive Power

     

        0

       (8)   

    Shared Dispositive Power

     

        3,385,317

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        3,385,317

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        9.93%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        IA


    CUSIP No. T9224W109
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Equity Funds

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)   Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        0

       (6)   

    Shared Voting Power

     

        2,254,454

       (7)   

    Sole Dispositive Power

     

        0

       (8)   

    Shared Dispositive Power

     

        2,254,454

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        2,254,454

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        6.61%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        IV


    CUSIP No. T9224W109
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Genesis Fund

        

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)   Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        0

       (6)   

    Shared Voting Power

     

        2,254,454

       (7)   

    Sole Dispositive Power

     

        0

       (8)   

    Shared Dispositive Power

     

        2,254,454

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        2,254,454

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        6.61%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        IV


    Item 1.
    (a) Name of Issuer
    Stevanato Group S.p.A.
    (b) Address of Issuer's Principal Executive Offices
    PIOMBINO DESE (PD) VIA MOLINELLA, 17
    PADUA, Italy, 35017

    Item 2.
    (a) Name of Person Filing
    Neuberger Berman Group LLC
    Neuberger Berman Investment Advisers LLC
    Neuberger Berman Equity Funds
    Neuberger Berman Genesis Fund
    (b) Address of Principal Business Office or, if none, Residence
    1290 Avenue of the Americas
    New York, NY 10104
    (c) Citizenship
    Delaware
    (d) Title of Class of Securities
    Common
    (e) CUSIP Number
    T9224W109

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)
    [   ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)
    [   ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [   ]
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [   ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [   ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [   ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [   ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [   ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [   ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ x ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4.
    (a) Amount beneficially owned:
    3,385,317

    Neuberger Berman Trust Co N.A., Neuberger Berman Trust Co of Delaware N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, and Neuberger Berman Investment Advisers LLC and certain affiliated persons may be deemed to beneficially own the securities covered by this report in their various fiduciary capacities by virtue of the provisions of Exchange Act Rule 13d-3. Neuberger Berman Group LLC, through its subsidiaries Neuberger Berman Investment Advisers Holdings LLC and Neuberger Trust Holdings LLC controls Neuberger Berman Trust Co N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, Neuberger Berman Trust Co of Delaware N.A. and Neuberger Berman Investment Advisers LLC and certain affiliated persons.

    This report is not an admission that any of these entities are the beneficial owner of the securities covered by this report and each of Neuberger Berman Group LLC, Neuberger Berman Investment Advisers Holdings LLC, Neuberger Trust Holdings LLC, Neuberger Berman Trust Co N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, Neuberger Berman Trust Co of Delaware N.A. and Neuberger Berman Investment Advisers LLC and certain affiliated persons disclaim beneficial ownership of the securities covered by this statement pursuant to Exchange Act Rule 13d-4.

    The information in this filing reports securities of the issuer that may be deemed to be beneficially owned by Neuberger Berman Group LLC, Neuberger Berman Investment Advisers Holdings LLC, Neuberger Trust Holdings LLC, Neuberger Berman Trust Co N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, Neuberger Berman Trust Co of Delaware N.A. and Neuberger Berman Investment Advisers LLC ("NBG Filers"). The securities of the issuer, if any, that may be deemed to be beneficially owned by NB Alternatives Advisers LLC and other subsidiaries of Neuberger Berman Group LLC that are separated from the NBG Filers by an information barrier in accordance with SEC Release No. 34-39538 (January 12, 1998) are not reflected in this filing.
    (b) Percent of class:
    9.93%
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote
    0
    (ii) Shared power to vote or to direct the vote
    3,346,671
    (iii) Sole power to dispose or to direct the disposition of
    0
    (iv) Shared power to dispose or to direct the disposition of
    3,385,317

    Item 5. Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ]

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Neuberger Berman Group LLC and its affiliates may be deemed to be beneficial owners of securities for purposes of Exchange Act Rule 13d-3 because they or certain affiliated persons have shared power to retain, dispose of or vote the securities of unrelated clients. Neuberger Berman Group LLC or its affiliated persons do not, however, have any economic interest in the securities of those clients. The clients have the sole right to receive and the power to direct the receipt of dividends from or proceeds from the sale of such securities. Other than named in this filing, no one client has an interest of more than 5% of the issuer.

    With regard to the shares set forth under item 4(c)(ii), Neuberger Berman Group LLC may be deemed to be the beneficial owner for purposes of Rule 13d-3 because certain affiliated persons have shared power to retain, dispose of and vote the securities. In addition to the holdings of individual advisory clients, Neuberger Berman Investment Advisers LLC serves as investment manager of Neuberger Berman Group LLC's various registered mutual funds which hold such shares. The holdings belonging to clients of Neuberger Berman Trust Co N.A., Neuberger Berman Trust Co of Delaware N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC and Neuberger Berman Investment Advisers LLC are also aggregated to comprise the holdings referenced herein.

    In addition to the shares set forth under Item 4(c)(ii) for which Neuberger entities also have shared power to dispose of the shares, item 4(c)(iv) also includes shares from individual client accounts over which Neuberger Berman Investment Advisers LLC has shared power to dispose but does not have voting power over these shares. The holdings of Neuberger Berman Trust Co N.A., Neuberger Berman Trust Co of Delaware N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC and Neuberger Berman Investment Advisers LLC, are also aggregated to comprise the holdings referenced herein.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
    N/A

    Item 8. Identification and Classification of Members of the Group.
    N/A

    Item 9. Notice of Dissolution of Group.
    N/A

    Item 10. Certification.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


     
    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date:   February 12, 2024
    Neuberger Berman Group LLC
    By: /s/ Brad Cetron

    Name: Brad Cetron
    Title: Managing Director
    Date:   February 12, 2024
    Neuberger Berman Investment Advisers LLC
    By: /s/ Brad Cetron

    Name: Brad Cetron
    Title: Managing Director
    Date:   February 12, 2024
    Neuberger Berman Equity Funds
    By: /s/ Brian Kerrane

    Name: Brian Kerrane
    Title: Chief Operating Officer
    Date:   February 12, 2024
    Neuberger Berman Genesis Fund
    By: /s/ Brian Kerrane

    Name: Brian Kerrane
    Title: Chief Operating Officer


    Get the next $STVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STVN

    DatePrice TargetRatingAnalyst
    12/2/2025$24.00Equal-Weight
    Morgan Stanley
    12/13/2024$28.00Outperform
    Wolfe Research
    12/3/2024$23.00Equal-Weight
    Morgan Stanley
    4/22/2024Outperform
    Exane BNP Paribas
    11/1/2023$39.00 → $29.00Buy → Hold
    Jefferies
    9/26/2023$33.00Overweight
    Stephens
    9/19/2023Market Outperform
    CJS Securities
    8/24/2023$34.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $STVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

    Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

    11/6/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Participate in Upcoming Investor Conferences

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences. Monday, November 17, 2025, at 8:40 a.m. ET - The 7th Annual Wolfe Research Healthcare Conference in New York City Wednesday, November 19, 2025, at 11:00 a.m. GMT - The Jefferies Global Healthcare Conference in London A live webcast of each event will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

    10/31/25 7:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

    10/22/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Stevanato Group S.p.A.

    SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    12/3/25 2:38:08 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Stevanato Group S.p.A.

    6-K - Stevanato Group S.p.A. (0001849853) (Filer)

    11/18/25 4:00:03 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Stevanato Group S.p.A.

    6-K - Stevanato Group S.p.A. (0001849853) (Filer)

    11/6/25 4:10:20 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

    Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $24.00

    12/2/25 8:34:50 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Wolfe Research initiated coverage on Stevanato Group S.p.A. with a new price target

    Wolfe Research initiated coverage of Stevanato Group S.p.A. with a rating of Outperform and set a new price target of $28.00

    12/13/24 8:24:13 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

    Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $23.00

    12/3/24 8:38:45 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Leadership Updates

    Live Leadership Updates

    View All

    Stevanato Group Announces Results of Annual General Meeting

    -All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, th

    5/24/24 4:10:00 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group appoints Ugo Gay as Chief Operations Officer

    Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404727049/en/Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire) The addition of Ugo Gay underscores Stevanato Group's unwavering commitment to driving opera

    4/4/24 8:00:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group Appoints Riccardo Butta as President, Americas

    The appointment bolsters company's commitment to growth in the region Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005514/en/Riccardo Butta (Photo: Business Wire) The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, accelerate i

    2/2/22 8:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Financials

    Live finance-specific insights

    View All

    Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

    Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

    11/6/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

    10/22/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

    Company delivers 8% revenue growth, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210 basis points to 28.1%. Diluted earnings per share were €0.11; adjusted diluted earnings per share were €0.11. Adjusted EBITDA mar

    8/5/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 4:06:28 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 3:30:56 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Stevanato Group S.p.A.

    SC 13G - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 1:28:35 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care